Therefore, PD-L1 blockade therapy reduced mTOR activity and mTOR–mediated upregulation of glycolysis in tumor cells, which, in turn allowing more available glucose within the extracellular milieu of the tumor and restores TILs glycolytic capacity and, as a result, their effector function (83). The gene discussed is CD274; the disease is neoplasm.